Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Minority Interest (2024 - 2025)

Ultragenyx Pharmaceutical has reported Minority Interest over the past 2 years, most recently at $7.0 million for Q4 2025.

  • Quarterly Minority Interest changed 0.0% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $7.0 million for FY2025, 0.0% changed from the prior year.
  • Minority Interest was $7.0 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $7.0 million in the prior quarter.
  • Over five years, Minority Interest peaked at $7.0 million in Q3 2024 and troughed at $7.0 million in Q3 2024.